Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
Recursion Pharmaceuticals has reached an agreement with the FDA on the design of its registrational Phase 3 clinical trial for REC-4881, an investigational oral MEK1/2 inhibitor for treating familial adenomatous polyposis (FAP).